Nadia Yaqub has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors. I’m sure you’ll agree that’s quite the statement from Motley Fool Co-Founder Tom Gardner.But since our US analyst team first recommended shares in this unique tech stock back in 2016, the value has soared.What’s more, we firmly believe there’s still plenty of upside in its future. In fact, even throughout the current coronavirus crisis, its performance has been beating Wall St expectations.And right now, we’re giving you a chance to discover exactly what has got our analysts all fired up about this niche industry phenomenon, in our FREE special report, A Top US Share From The Motley Fool. See all posts by Nadia Yaqub “This Stock Could Be Like Buying Amazon in 1997” Simply click below to discover how you can take advantage of this. Enter Your Email Address Image source: Getty Images. Click here to claim your copy now — and we’ll tell you the name of this Top US Share… free of charge! Over the past half year, the Draper Esprit (LSE:GROW) share price has increased significantly, rising 65% at the time of writing.The AIM-listed venture capital firm, which invests in European technology businesses, allows investors to gain access to a portfolio of some of Europe’s fastest growing private, pre-IPO, technology businesses.5G is here – and shares of this ‘sleeping giant’ could be a great way for you to potentially profit!According to one leading industry firm, the 5G boom could create a global industry worth US$12.3 TRILLION out of thin air…And if you click here we’ll show you something that could be key to unlocking 5G’s full potential…Draper Esprit’s core portfolio is concentrated, where 67% is invested across 16 companies. These include well-known names such as the online global review site Trustpilot, and the challenger bank, Revolut.Seed stage investorDraper Esprit shares also allow investors access to early-stage technology companies, through its seed fund investment strategy, which invests in other early-stage technology funds. Revealed at its full-year results in June 2020, it has invested £39m across 20 seed funds to date. Draper Esprit’s seed fund portfolio complements its existing core portfolio and allows the firm to diversify its exposure to European technology companies across the business life-cycle.Fund raisingWith an active history of placings, Draper Esprit announced a successful placing early October 2020, raising £110m. The Covid-19 pandemic has accelerated the shift to digital technology, and as such Draper Esprit has had to support its portfolio of businesses that cover services such as online payments and fraud detection.The proceeds from the placing will allow Draper Esprit to deploy funds into new potential future investment opportunities, further diversifying its overall portfolio. It will also allow Draper Esprit to contribute to follow-on funding rounds for its existing portfolio of companies with a view to exit for an attractive Return On Investment (ROI).Recent activityThe rally in the Draper Esprit share price reflects that the company is an active European venture capital investor. In October 2020 it co-led the $50m series B fundraising of PrimaryBid, a technology platform that allows retail investors access to public companies raising capital.It was announced in June 2020 that Zynga would acquire 100% of the Istanbul-based mobile developer Peak Games for $1.8bn. Draper Esprit’s investment upon sale was worth approximately £80m.Over recent months, Draper Esprit has successfully disposed of its investment in TransferWise, the international money transfer platform. It has led the $20m Series C investment into Ravelin, a fraud detection company. Ravelin uses machine learning and graph network technologies to help online businesses accept more payments with confidence.A positive updateDraper Esprit posted a mid-year update ahead of its interim results scheduled for release on 30th November 2020. The venture capitalist expects its Gross Portfolio Value to be no less than £695m, and has seen a Gross Portfolio Fair Value increase of £70m over the six-month period, which includes the uplift from the disposals of Peak Games and TransferWise. Draper Esprit remains in a strong position to invest in technology businesses with cash resources at year-end of £62m.An encouraging outlookI believe the mid-year update is a sign of positive prospects for the Draper Esprit share price. Investments such as the telemedicine company Push Doctor has allowed Draper Esprit to benefit from the Covid-19 technology boom, which I expect will continue. The management team have successfully displayed their ability to identify, invest and exit European technology companies. Renowned stock-picker Mark Rogers and his analyst team at The Motley Fool UK have named 6 shares that they believe UK investors should consider buying NOW.So if you’re looking for more stock ideas to try and best position your portfolio today, then it might be a good day for you. Because we’re offering a full 33% off your first year of membership to our flagship share-tipping service, backed by our ‘no quibbles’ 30-day subscription fee refund guarantee. Nadia Yaqub | Friday, 20th November, 2020 | More on: GROW Our 6 ‘Best Buys Now’ Shares I would like to receive emails from you about product information and offers from The Fool and its business partners. Each of these emails will provide a link to unsubscribe from future emails. More information about how The Fool collects, stores, and handles personal data is available in its Privacy Statement. Why the Draper Esprit share price is up 65% in 6 months
Please enter your name here Risk-reducing surgeries like salpingo-oophorectomies and preventive mastectomies have been in the news a lot lately, in part because celebrities like Applegate and Angelina Jolie have spoken out about their experiences with the BRCA1 and BRCA2 gene mutation. These (and other) mutations can sharply raise a woman’s risk of developing certain cancers over her lifetime.We spoke with Florida Hospital gynecologic oncologist Dr. Natalie Dauphin McKenzie, who is also a breast cancer survivor, for an in-depth look at who’s at risk and what they can do to protect their health — in body, mind, and spirit.Q: First of all, could you explain the BRCA gene mutation?A: BRCA is a gene that is a transcript for a protein that is involved in DNA repair. We know that when DNA repair is faulty or there are other defects in the DNA that sometimes cancer can ensue. In other words, when the gene is mutated it puts the person at risk for certain cancers.BRCA1 and BRCA2 are some of the first genes that were discovered to be involved as a hereditary mutation involved in breast and ovarian cancers. Since then, many other genetic mutations have been discovered, but BRCA1 and BRCA2 are the more common hereditary mutations that put women and other family members at risk for different types of cancer.Q: What is the “why” behind ovary and fallopian tube removal?A: Studies have found that women who undergo what we call a risk-reducing procedure – whether it’s a risk-reducing mastectomy or a risk-reducing salpingo-oophorectomy (removal of the tube and ovary) –significantly reduce their risk of developing ovarian cancer, and even breast cancer.Q: So having ovaries removed can reduce breast cancer risk as well?A: Yes. Specifically, there is data to show that removing the tubes and ovaries decreases the risk of developing these types of ovarian cancers by 85–90 percent. Some studies have shown a decrease by 50 percent of developing some breast cancers if the tubes and ovaries removed in a woman with the BRCA mutations. Not only does removing the tubes and ovaries decrease the risk of ovarian cancer and breast cancer, it also has been shown to decrease overall mortality in women with BRCA1 or BRCA2 genetic mutation.Q: Do you perform this surgery? Could you tell us about it?A: Yes, I do perform risk-reducing salpingo-oophorectomies.I have performed the procedure on patients who got genetic testing after finding out they had breast cancer. These women are usually referred to me to discuss the procedure and then proceed if that is what they want. In rare cases, it has been performed for patients whose BRCA testing was negative, but who had an extremely strong family history.For some patients, I can do the entire procedure through their belly button through single-incision laparoscopic surgery (SILS). It’s often called “scarless surgery” because, after the surgery, you can barely see the little scar in the belly button.Q: Once the ovaries are removed, is the threat of ovarian cancer completely eliminated?A: It drastically reduces the risk. Unfortunately, the risk does not go down to zero. For example, at the time a woman undergoes this procedure, a malignant transformation may already have occurred. These situations are incredibly sad.There’s also a type of cancer called primary peritoneal carcinoma, in the same family as fallopian tube cancer and epithelial ovarian cancer. Primary peritoneal cancer can still happen over the lifetime of BRCA1 or BRCA2 patients. After having undergone a risk-reducing salpingo-oophorectomy, the lifetime risk is 4.3 percent.Q: Which women are considered good candidates for this surgery?A: Usually, expert recommendations are that it be offered to women by age 40 after they have completed their family planning. On average, we tend to see that women do this between ages 35 and 40, with some exceptions.Q: Is the surgery exclusively for women who have tested positive for BRCA1 or BRCA2?A: We can’t say exclusively because our science is evolving, as is our ability to detect new genetic mutations. We have learned to not have too strict of guidelines because we may meet a patient who tests negative for BRCA1 and BRCA2 but has a very strong family history, and we couldn’t ignore that.Q: What risks are associated with salpingo-oophorectomy?A: In the hands of a very skilled surgeon, the risks are minimal. Especially if an expert such as a gynecologic oncologist undertakes the procedure. Surgery is not without risk, however. There’s always a certain small percentage risk of injury to nearby organs, bleeding or infection.Q: Ovary removal brings on menopause. Could you talk about that?A: Sure. The ovaries are responsible for releasing the female hormones that regulate multiple female bodily functions and cyclical functions. These are the same hormones that have the feedback mechanism of the brain that controls our monthly cycles.With menopause, the hormones that were produced by the ovaries are now absent. So the female body goes into menopause immediately upon removal of the ovaries, and she undergoes a new equilibrium with the absence of these hormones.These hormones do contribute to a woman’s overall well-being and bone health. Some studies show that female hormones also contribute to cognitive function. The absence of these female hormones definitely can have some effects on a woman, which is why we don’t routinely recommend that a woman with average risk undergo this type of procedure – because the risk-benefit ratio for the average woman doesn’t support the removal of the tubes and ovaries. Whereas in somebody who has a very high risk of developing a very deadly cancer, the scales are tipped in favor of surgery.Q: Which women do you recommend seek genetic testing?A: So far, we recommend [genetic counseling] for women who have a family history, especially if there are at least two families members with cancer. Eventually, technology will continue to improve and the test will become more available to the population, but right now the costs can be prohibitive for many people. I’ve even had patients who had ovarian cancer tell me they couldn’t afford the test.Q: Do we know how many women have BRCA gene mutations?A: What we do know is that of the women who have been diagnosed with ovarian cancer and tested, approximately 10 percent of those have specific BRCA1 or BRCA2 mutation with another 17 percent having BRCA in the tumor itself—this is important to know because BRCA ovarian cancer patient has certain additional treatment options available to them.[Primarily] patients who appear to have a family history are getting tested for the gene, so we’re unlikely to ever know unless we were to test everybody in the population to see who is truly BRCA or not. What we can consistently do is try and test every ovarian cancer patient, and then at least know more or less how many in that population harbor the gene. Certain populations have an elevated risk and in those populations’ genetic testing is more commonly performed.Q: With stories like Christina Applegate’s and Angelina Jolie’s, are risk-reducing surgeries becoming more common?A: Yes, with Angelina’s story and Christina Applegate’s story we have certainly seen an increase in office visits with specific requests and certain questions that typically were less commonly asked in the past. In my practice, I have seen more requests and more discussion surrounding this topic.Q: Overall, is this positive for public health awareness?A: Absolutely. At first, there was a little bit of a scare that women who maybe were not necessarily at risk were alarmed and wanted to better understand what they were hearing in the news, but over time there has continued to be really good, healthy questions and discussion around this topic.Q: Could you tell us about your personal experience with breast cancer?A: I was very young when I was diagnosed. I was diagnosed 10 days before my 31st birthday. I actually spent my 31st birthday getting a PET scan to look for metastases. I was a newlywed at the time.Although scary, I was lucky (a little bit,) in the sense that I was already a medical professional at the time, though sometimes when you know too much it’s even more alarming! I recall as young newly-wed going through breast cancer diagnosis, surgery then chemotherapy and thinking how intimidating it all felt. After all, it was something that I typically associated with older women–menopausal women — people who have already had their families and raised their kids.I chose to have a double mastectomy; these are life-altering, body image-altering experiences for a young woman. For me, I thought – and still, think – it was the best decision that I made for myself as an individual. I believe every person is different and has to make their own decision as an individual.I’ve also had family members diagnosed with breast cancer, and every woman made her own individual decisions with regards to her surgery (or lack thereof) and the type of treatment she chose for herself. Even in the same family, people may choose different treatments that are best suited for them.Q: Are you BRCA1 or BRCA2 positive?A: No, I am not positive for BRCA1 or BRCA2. But now that there are a plethora of other genes that have since been discovered, I look forward to setting up my appointment with a genetic counselor and getting tested to maybe better explain the strong family history of cancer that we have.Q: What can women expect if they decide to undergo gene testing?A: [Florida Hospital] has a great support network with great nurse advocates who can help patients through genetic counseling and testing, and direct them to our high-risk breast clinic and gynecologic oncologists if the case necessitates for either discussion of genetic testing. If a patient is found to be “high-risk” they can be channeled to the right professional to have a discussion about risk-reducing procedures. UF/IFAS in Apopka will temporarily house District staff; saves almost $400,000 Florida gas prices jump 12 cents; most expensive since 2014 Share on Facebook Tweet on Twitter You have entered an incorrect email address! Please enter your email address here The VOICE of HealthFrom Florida Hospital Apopka Gov. DeSantis says new moment-of-silence law in public schools protects religious freedom Please enter your comment! LEAVE A REPLY Cancel reply TAGSFlorida Hospital – ApopkaThe VOICE of Health Previous articleApopka Burglary ReportNext articleCity begins “second pass” on hurricane cleanup Denise Connell RELATED ARTICLESMORE FROM AUTHOR Save my name, email, and website in this browser for the next time I comment.
When roommates Kwame Vaughn and D.J. Seeley battle it out over a game of Fight Night, NBA 2K or zombies in Call of Duty, Vaughn comes out victorious.But that’s only according to Vaughn.“I’m the best at it,” Seeley said. “He’s laughing. He’s lying.”That competitive energy has spilled onto the court as well, where Seeley holds another advantage: a slight lead over his fellow senior co-captain in the Big West Conference scoring column. The California State Fullerton (11-9, 4-4 BWC) guards are two of the top-three scorers in the conference for a Titans offense that ranks No. 3 nationally in points per game. At Seeley’s rate of 19.2 points per contest, which is good for 26th in the country, he trails the Big West’s first-place holder by just 0.2 points per contest.Vaughn isn’t too far behind his backcourt mate, averaging 17.8 points per game, helping to pace a CSF team that sits in the top 10 nationally in a few offensive categories.AdvertisementThis is placeholder textTitans first-year head coach Andy Newman has the luxury of having not one but two proven scorers on the court when CSF needs a basket.“Oh, it’s phenomenal. It’s great,” Newman said. “When you have two guys on the floor that can score from anywhere it really helps. It’s really a huge asset for us.”But the Titans didn’t have either of those options two years ago. Both members of the Class of 2008, the guards started their college careers elsewhere.Seeley was a highly rated recruit out of high school in Modesto, Calif. – a top-50 prospect who reached the radars of powerhouses such as Duke and UCLA. Seeley committed to California and played for the Golden Bears for two seasons, even though head coach Ben Braun had been fired before Seeley’s arrival.On the other hand, CSF had its eyes on Vaughn out of Oakland, Calif., but decided it didn’t need a point guard from that recruiting class. Vaughn instead signed with nearby San Francisco, and was the Dons’ second-leading scorer for two years.In neither of Seeley’s two seasons at Cal did he average more than 2.5 points per game or start a game. Simultaneously, Vaughn wasn’t in an ideal role either, despite the statistical success.“It wasn’t the right situation or the right program,” Vaughn said. “Not my style of play. I was playing shooting guard as well.”Conveniently, the Titans found themselves needing a point guard after Jacques Streeter transferred to Texas-El Paso. CSF was back on the recruiting scene and lured in Vaughn and Seeley with its wide-open, NBA-style offense.“(They) wanted to play and play fast, score a lot of points, get back to having fun playing basketball,” Newman said. “It’s a fun, open style of basketball, that’s for sure.”CSF has always brought in good transfers, Newman said. When transfers sit out the season due to NCAA transfer regulations, Newman said, they are placed on a “redshirt” team and practice against the Titans as a scout team.Vaughn and Seeley, who played together once before in an AAU tournament, redshirted the 2010-11 season, which Newman said helped them understand how to play with each other’s style.At the same time, the two developed a friendship, finding that they shared similar interests off of the court. They’re both religious, Vaughn said, and have similar backgrounds, which helped spark the friendship.Fresh off the redshirt year, the guards burst to the top of the Titans’ stat sheets and finished one-two in the CSF scoring column. CSF jumped from sixth to second place in the Big West in its first season with Vaughn and Seeley on the court.Opposing coaches can’t draw up anything that will stop both of them, Newman said.“The one thing about both of them is they’re complete players,” Newman said. “A lot of times in the college level, you have guys who can shoot it but they can’t penetrate. Or they can penetrate and they can’t shoot it. These guys have the total package.”This season, the Titans have been plagued with injuries, but its offense is still thriving as Seeley and Vaughn have grown into their leadership roles as co-captains. Out of CSF’s 20 games this year, the duo has combined for 40 points on seven separate occasions. They’ve totaled as much as 59, which was accomplished Jan. 5 and spearheaded by a 37-point performance by Seeley.Newman will leave it to NBA general managers to determine Seeley and Vaughn’s future, but he believes his players have what it takes to succeed at the next level.“I certainly know they possess the skill level, the talent and the will to be there,” Newman said. “I never have to worry about if they’re working out. If anything, I need to monitor how much they’re doing so they’re not wearing themselves out.” Comments Published on January 29, 2013 at 1:01 am Contact Phil: [email protected] | @PhilDAbb Facebook Twitter Google+
Ghana midfielder Derek Boateng has completed a two-year deal to join Fulham. Boateng will join Fulham this summer for their pre-season training to start his career with the Cottagers.The Ghana midfielder signed for Martin Jol’s men, according to his friend, on a free transfer after snubbing late interest from Aston Villa.Boateng, 30, has seen moves from Ukrainian club Dnipro to Craven Cottage collapse last year and in January.But Fulham have finally got their man and he has put pen to paper on a two-year deal on a free transfer.The club have been heavily linked with the Ghana international over the past two transfer windows but grabbed their man after the third time of asking.Regardless, as a free agent, there would seem to be little risk in moving for a player that comes with reasonable pedigree. Capped 46 times, the central midfielder is full of energy and has an enviable work rate – both traits that would complement our current crop.However, he’s a player that is slow to adapt, having played all across Europe for eight different clubs and yet only excelling in a couple of those stints.He was superb with AIK in Sweden, and impressed with Beitar Jerusalem and Getafe.Elsewhere, though, he has failed to find his feet and, now that he has reached his thirties, there is not long left for Boateng to prove himself.Fulham could well bring the best out of the player, as we have done with many others in the past, but it could also prove to be a transfer fraught with risk.